jRCT2080225360已完成1 期
A Phase 1 study of H3B-6545 in Japanese women with estrogen receptor-positive, HER2 negative breast cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open Label
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- Female
入选标准
- •Subject has a histologically and/or cytologically confirmed diagnosis of ER-positive, HER2-negative breast cancer.
- •Note: Status of ER and HER2 should be diagnosed by method approved by regulatory authority
- •Only females, age >=20 years at the time of informed consent.
- •Prior therapy for breast cancer in the adjuvant and/or advanced/metastatic setting must have included a minimum of:
- •a) two prior hormonal therapies, or
- •b) one prior hormonal therapy and one prior chemotherapy regimen, or
- •c) one prior hormonal therapy and a CDK4/6 inhibitor.
- •Subject has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or
- •Subject has adequate bone marrow and organ function.
- •Subjects who are expected to survive for 3 months or longer after starting administration of the investigational drug.
- •Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.
排除标准
- •Subject with inflammatory breast cancer.
- •Subject is currently receiving or has received systemic corticosteroids =<2 weeks prior to starting study drug, or has not fully recovered from side effects of such treatment.
- •Subject has active cardiac disease or a history of cardiac dysfunction, including any of the following:
- •a. History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry.
- •b. History of documented congestive heart failure (New York Heart Association functional classification II to IV).
- •c. Documented cardiomyopathy.
- •d. Subject has a left ventricular ejection fraction (LVEF) <50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO).
- •e. History of any cardiac arrhythmias, eg, ventricular, supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.
- •f. Heart Rate <60 bpm on the screening.
- •g. On screening, any of the following cardiac parameters: PR interval >220 msec, QRS interval >109 msec, or QTcF >450 msec.
- •h. Systolic blood pressure (BP) not deemed clinically controlled by the investigator.
- •Subject has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug.
- •Known to be human immunodeficiency virus (HIV) positive.
- •Active viral hepatitis (B or C) as demonstrated by positive serology. Subjects with chronic HBV infection is on antiviral therapy is eligible.
- •Any adverse event related to previous therapies for breast cancer that has not resolved to =<Grade 1 (with exception of the alopecia).
- •Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [beta-hCG] or human chorionic gonadotropin [hCG] test).
- •Women of childbearing potential who don't agree that both the subject and her partner will use a medically effective method for contraception (as below) throughout the entire study period or for 28 days after study drug discontinuation.
- •If a subject is on oral contraceptives, they should also be using some additional method.
- •Alcohol dependency within 6 months before study entry.
- •Subject has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, or curatively resected cervical cancer.
- •Diagnosed with meningeal carcinomatosis.
- •Subjects with brain or subdural metastases.
- •Subject has a known intolerability to any oral antihistamine drug (only for Antihistamine Prophylactic Administration Part and Randomization Part).
- •Subject needs to receive systemic or topical usage of either antihistamine or corticosteroid during Cycle 1 (only for Randomization Part).
- •Subject has initiated to receive drugs may cause rash 7 days prior to starting study drug.
结局指标
主要结局
-
safety DLT, AE
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 study of H3B-6545 in Japanese women with estrogen receptor-positive, HER2 negative breast cancerJPRN-jRCT2080225360Eisai Co., Ltd.33
已完成
1 期
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast CancerBreast NeoplasmsNCT04568902Eisai Co., Ltd.33
进行中（未招募）
不适用
Phase 3 study of HPN-100 in Japanese patients with urea cycle disorderUrea cycle disorderjRCT2071220110OrphanPacific, Inc.15
未知
1 期
A phase 1/2 study of E6005 in Japanese patients with atopic dermatitisAtopic dermatitsJPRN-jRCT2080221229Eisai Co., Ltd.40
已完成
不适用
Phase 1 study of BAY 2586116 in Japanese healthy male participants (Phase 1 study of BAY 2586116 in Japanese healthy male participants)jRCT2071210020Bayer Yakuhin, Ltd.36